ADMA Biologics Inc
| NASDAQ: ADMA | Healthcare / Biotechnology / USA |
| 3.81 | +0.1100 | +2.97% | Vol 1.69M | 1Y Perf 14.55% |
| Dec 1st, 2023 16:00 DELAYED |
| BID | 3.60 | ASK | 3.84 | ||
| Open | 3.70 | Previous Close | 3.70 | ||
| Pre-Market | - | After-Market | 3.81 | ||
| - - | - -% |
| Target Price | 5.13 | Analyst Rating | Strong Buy 1.00 | |
| Potential % | 34.65 | Finscreener Ranking | ★★★+ 50.99 | |
| Insiders Trans % 3/6/12 mo. | -/-/100 | Value Ranking | ★ 39.53 | |
| Insiders Value % 3/6/12 mo. | -/-/100 | Growth Ranking | ★ 37.09 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/100 | Income Ranking | — - | |
| Price Range Ratio 52W % | 50.73 | Earnings Rating | Buy | |
| Market Cap | 860.94M | Earnings Date | 8th Nov 2023 | |
| Alpha | -0.00 | Standard Deviation | 0.15 | |
| Beta | 0.79 |
Today's Price Range 3.643.83 | 52W Range 2.954.65 | 5 Year PE Ratio Range -1.60-3.50 |
Summary:
Buy
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Buy |
| Performance | |||
|---|---|---|---|
| 1 Week | -3.79% | ||
| 1 Month | 10.43% | ||
| 3 Months | -2.06% | ||
| 6 Months | -5.93% | ||
| 1 Year | 14.55% | ||
| 3 Years | 91.46% | ||
| 5 Years | -27.70% | ||
| 10 Years | -52.08% |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -80.56 | |||
ROE last 12 Months | -69.23 | |||
ROA (5Y Avg) | -14.40 | |||
ROA last 12 Months | -26.08 | |||
ROC (5Y Avg) | -52.83 | |||
ROC last 12 Months | -23.38 | |||
Return on invested Capital Q | -3.60 | |||
Return on invested Capital Y | -5.94 | |||
Assets Turnover | 0.20 | |||
Receivables Turnover | 1.90 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -10.40 | ||||
| 7.99 | ||||
| 7.45 | ||||
| - | ||||
| -12.90 | ||||
| -0.44 | ||||
| 8.38 | ||||
| 0.45 | ||||
| 919.70M | ||||
| Forward PE | 24.75 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 1.30 | ||||
| 5.00 | ||||
| 0.60 | ||||
| 1.52 | ||||
| -3.20 | ||||
| Leverage Ratio | 2.60 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 18.90 | ||||
| -41.00 | ||||
| -35.80 | ||||
| -197.30 | ||||
| -51.56 |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 104.10M | ||||
| 0.47 | ||||
| 61.94 | ||||
| 42.00 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q02 2023 | -0.02 | -0.02 | 0.00 |
| Q01 2023 | -0.05 | -0.03 | 40.00 |
| Q04 2022 | -0.07 | -0.06 | 14.29 |
| Q03 2022 | -0.08 | -0.08 | 0.00 |
| Q02 2022 | -0.09 | -0.07 | 22.22 |
| Q01 2022 | -0.08 | -0.10 | -25.00 |
| Q04 2021 | -0.10 | -0.09 | 10.00 |
| Q03 2021 | -0.15 | -0.13 | 13.33 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 12/2023 QR | 0.01 | - | - |
| 12/2023 FY | -0.03 | 50.00 | Positive |
| 3/2024 QR | 0.02 | - | - |
| 12/2024 FY | 0.16 | 33.33 | Positive |
| Next Report Date | - |
| Estimated EPS Next Report | -0.01 |
| Estimates Count | 2 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 1.69M |
| Shares Outstanding | 225.97K |
| Shares Float | 196.59M |
| Trades Count | 10.67K |
| Dollar Volume | 6.39M |
| Avg. Volume | 1.59M |
| Avg. Weekly Volume | 1.16M |
| Avg. Monthly Volume | 1.87M |
| Avg. Quarterly Volume | 1.75M |
ADMA Biologics Inc (NASDAQ: ADMA) stock closed at 3.81 per share at the end of the most recent trading day (a 2.97% change compared to the prior day closing price) with a volume of 1.69M shares and market capitalization of 860.93M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 314 people. ADMA Biologics Inc CEO is Adam S. Grossman.
The one-year performance of ADMA Biologics Inc stock is 14.55%, while year-to-date (YTD) performance is -1.8%. ADMA stock has a five-year performance of -27.7%. Its 52-week range is between 2.945 and 4.65, which gives ADMA stock a 52-week price range ratio of 50.73%
ADMA Biologics Inc currently has a PE ratio of -10.40, a price-to-book (PB) ratio of 7.99, a price-to-sale (PS) ratio of 7.45, a price to cashflow ratio of -, a PEG ratio of -, a ROA of -26.08%, a ROC of -23.38% and a ROE of -69.23%. The company’s profit margin is -51.56%, its EBITDA margin is -35.80%, and its revenue ttm is $104.10 Million , which makes it $0.47 revenue per share.
Of the last four earnings reports from ADMA Biologics Inc, there were 2 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.01 for the next earnings report. ADMA Biologics Inc’s next earnings report date is -.
The consensus rating of Wall Street analysts for ADMA Biologics Inc is Strong Buy (1), with a target price of $5.13, which is +34.65% compared to the current price. The earnings rating for ADMA Biologics Inc stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
ADMA Biologics Inc has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
ADMA Biologics Inc has a Buy technical analysis rating based on Technical Indicators (ADX : 19.27, ATR14 : 0.15, CCI20 : -16.43, Chaikin Money Flow : -0.08, MACD : 0.08, Money Flow Index : 52.70, ROC : 1.87, RSI : 55.47, STOCH (14,3) : 39.53, STOCH RSI : 0.36, UO : 38.02, Williams %R : -60.47), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of ADMA Biologics Inc in the last 12-months were: Adam S. .Grossman (Option Excercise at a value of $4 721 099), Adam S. .Grossman (Sold 760 472 shares of value $3 355 042 ), Brian Lenz (Option Excercise at a value of $1 904 948), Brian Lenz (Sold 389 762 shares of value $1 766 178 ), Grossman Jerrold (Buy at a value of $482 300), Young T. Kwon (Buy at a value of $97 500)
ADMA Biologics Inc
ADMA Biologics Inc is a United States-based biopharmaceutical company. It is engaged in the manufacture, marketing and development of specialty plasma-derived biologics. The operating segments of the company are ADMA BioManufacturing segment; Plasma Collection Centers segment; and Corporate segment. The Plasma Collection Centers segment consists of three FDA-licensed source plasma collection facilities located in Georgia. The company's ADMA BioManufacturing segment reflects the company's immune globulin manufacturing and development operations in Florida.
CEO: Adam S. Grossman
Telephone: +1 201 478-5552
Address: 465 State Route 17, Ramsey 07446, NJ, US
Number of employees: 314
